A rare variant in DPYD c.812delT causes severe adverse events of S-1 in a patient with tongue cancer

Cancer Chemotherapy and Pharmacology · Published 2026-08-03 · DOI 10.1007/s00280-026-04930-9

Free full text

Authors (15)

Hiroki Ishimura, Atsushi Suehiro, Daiki Hira, Eiji Hishinuma, Midori Kato, Masamitsu Maekawa, Taishi Yasuda, Yurie Katsube, Yoshiki Katada, Natsuki Imayoshi, Yuki Shigetsura, Shunsaku Nakagawa, Masahiro Tsuda, Masahiro Hiratsuka, Tomohiro Terada

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Ishimura, H., Suehiro, A., Hira, D., et al. (2026). A rare variant in DPYD c.812delT causes severe adverse events of S-1 in a patient with tongue cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-026-04930-9

Related articles

• Deciphering autophagy-metabolism interactions in cancer drug resistance: a comprehensive review · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Pharmacokinetic and pharmacogenomic profile of capecitabine and oxaliplatin in a patient with gastric cancer undergoing hemodialysis: a case report · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Temozolomide resistance in glioma: aligning target discovery with clinically achievable CNS exposures and translational delivery strategies · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Physiologically based pharmacokinetic modeling of granisetron for optimizing antiemetic therapy in patients with cancer: multi-route pharmacokinetic characterization and target-site exposure prediction · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Transfer of trastuzumab and pertuzumab into human breast milk: a case report · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Synergistic anti-tumor activity of andrographolide and gemcitabine in intrahepatic cholangiocarcinoma through inhibition of RRM2 and the JAK/STAT3 pathway · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Pharmacologic de-escalation of dexamethasone during weekly paclitaxel: a randomized phase III trial evaluating safety, endocrine effects, and quality of life · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• Antibody–drug conjugates in colorectal cancer: molecular design, preclinical advances, and translational challenges · Cancer Chemotherapy and Pharmacology · 2026 · Same journal
• The potential and promise of natural antioxidants as epigenetic modulators in oral squamous cell carcinoma · Cancer Chemotherapy and Pharmacology · 2026 · Same journal